EMA blesses ovarian cancer use for Roche's Avastin

Roche's Avastin won a new indication in ovarian cancer in Europe. The European Medicines Agency approved the drug for use in patients with newly diagnosed, advanced ovarian cancer, in combination with chemotherapy. Report

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.